Gynecologic Oncology

Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.

Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.

Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.

Apatinib exerts anti-tumour effects on ovarian cancer cells.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥\u202f70\u202fyears) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.

A prospective clinical cohort study of women at increased risk for endometrial cancer.

Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.

MUC16 suppresses human and murine innate immune responses.

A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.

Pathological process has a crucial role in sentinel node biopsy for vulvar cancer.

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma

Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins.

Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.

Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development.

Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?

Non-pegylated liposomal doxorubicin (NPLD, Myocet®)\u202f+\u202fcarboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study.

Risk factors for failure of bilateral sentinel lymph node mapping in early-stage cervical cancer.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.

Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.

Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.

The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.

Evidence-based wound classification for vulvar surgery: Implications for risk adjustment.

MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.

Extramammary Paget disease of the vulva: Management and prognosis.

Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.

A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.

Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.

Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.

Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilities.

Evolving population-based statistics for rare epithelial ovarian cancers.

Place of death by region and urbanization among gynecologic cancer patients: 2006-2016.

Step-by-step demonstration of laparoscopic laterally extended endopelvic resection for a recurrent endometrial cancerous tumor at a sciatic foramen, with a detailed explanation of the pelvic sidewall anatomy.

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma

Variation in resource utilization associated with the surgical management of ovarian cancer.

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.

Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.